Biomimetic Therapeutics — 2010 AOFAS Annual Summer Meeting
19 slides from Biomimetic Therapeutics's conference presentation, Jul 7, 2010

Slide 1: North American Pivotal Trial Review
North American Pivotal Trial Review Outcomes of a Randomized, Controlled, Trial to Evaluate Augment Bone Graft (rhPDGF-BB/ß-TCP) as a Replacement for Autograft in Hindfoot and Ankle Fusion 2010 AOFAS Annual Summer Meeting Washington, DC Presented By: Tim Daniels, MD – Toronto, ON

Slide 2: Disclosure
Disclosure Disclosures available on AOFAS Meeting Book In the United States, Augment Bone Graft is an investigational product and is not available for sale In Canada, Augment Bone Graft is an approved Class IV medical device and is indicated as a replacement for autograft in ankle, hindfoot and midf

Slide 3: Augment Bone Graft (rhPDGF-BB/ß-TCP)
Augment™ Bone Graft ( rhPDGF-BB/ß-TCP) Developed as a fully synthetic replacement for autograft Recombinant PDGF (rhPDGF-BB) FDA approved for tissue regeneration periodontal bone defects (GEM 21S ® ) diabetic foot ulcers (Regranex ® ) Prior Studies in Orthopedics pilot studies: foot/ankle, wrist

Slide 4: Pivotal Trial Objectives
Pivotal Trial Objectives HYPOTHESIS : Augment Bone Graft (rhPDGF-BB/ß-TCP) is non-inferior to autograft when used as a healing adjunct during hindfoot and ankle fusion surgery PRIMARY ENDPOINT : % patients fused by CT scan at 6 months, defined as ≥50% osseous bridging across the joint surface (per C

Slide 5: Study Protocol
Study Protocol 2:1 randomization, Augment™ (rhPDGF-BB/ß-TCP): Autograft Autograft from iliac crest, Gerdy’s, distal tibia, calcaneus Std joint preparation, ORIF using ≤ 3 screws/joint Post-op immobilization for 12 wks, NWB first 6 wk CT evaluation: 9, 16, 24, 36 wks XR evaluation: 1-3, 6, 9, 12, 16,

Slide 6: Largest clinical study ever performed in foot and ankle patients
Largest clinical study ever performed in foot and ankle 434 patients 37 clinical centers (USA/CAN) 72 investigators First of its kind with a recombinant protein Study Scope

Slide 7: Study Demographics
Study Demographics All Patients n= 434 Augment™ n= 285 Autograft n=149 Sex (M/F) 49.8% / 49.1% 46.3% / 52.3% 56.4% / 43.0% Age (Mean) 56.6 years 56.2 years 57.5 years BMI (Mean) 30.8 30.7 31.1 Diagnosis Post Traumatic OA 48.2% 48.8% 47.0% Primary Arthritis 34.3% 32.6% 37.6% Rheumatoid 6.7% 8.4% 3.4%

Slide 8: Clinical Example, Ankle
Clinical Example, Ankle

Slide 9: Radiographic Assessment
Radiographic Assessment 3 months Post-op Radiographs and clinical evaluation useful but not always reliable

Slide 10: CT Assessment
CT Assessment 6 weeks Post-op Multiple areas of Osseous-bridging

Slide 11: Patient Accountability
Patient Accountability Screened Population n=457 (456*) *Less one subject screened twice Randomized Population n=435 ITT Population n=434 Augment (285)/Autograft (149) mITT Population n=397 Augment (260)/Autograft (137) Not randomized n=21 Not randomized prior to treatment n=1 Excluded from mITT n=1

Slide 12: Radiographic Endpoints - 36/52 wks
Radiographic Endpoints -36/52 wks Augment N=260 Joints=394 Autograft N=137 Joints=203 Non- Inferiority (p-value) CT Fusion - 36 wks Full Complement of Joints 63.5% 69.3% No (0.202) All Joints 68.8% 73.9% No (0.103) XR Fusion (3 views) - 52 wks Full Complement of Joints 36.9% 36.5% Yes (0.020) All Jo

Slide 13: Radiographic Endpoints
Radiographic Endpoints – 24 wks Augment N=260 Joints=394 Autograft N=137 Joints=203 Non- Inferiority (p-value) CT Fusion Rate Full complement of joints 61.2% 62.0% Yes (0.038) All joints 66.5% 62.6% Yes (<0.001) XR Fusion (3 views) Full complement of joints 30.8% 32.8% No (0.054) All joints 38.3% 37

Slide 14: Radiographic Endpoints - 36/52 wks
Radiographic Endpoints - 36/52 wks Augment N=260 Joints=394 Autograft N=137 Joints=203 Non- Inferiority (p-value) CT Fusion - 36 wks Full Complement of Joints 63.5% 69.3% No (0.202) All Joints 68.8% 73.9% No (0.103) XR Fusion (3 views) - 52 wks Full Complement of Joints 36.9% 36.5% Yes (0.020) All J

Slide 15: Clinical Endpoints
Clinical Endpoints – 52 wks Augment N=260 Joints=394 Autograft N=137 Joints=203 Non-Inferiority (p-value) Clinical Healing (Investigator Assessed) Patient Level 87.7% 88.3% Yes (0.003) Full complement of joints 86.2% 87.6% Yes (0.008) All joints 88.3% 87.2% Yes (<0.001) Nonunion 4.2% 5.8% Yes (<0.00

Slide 16: Functional Endpoints
Functional Endpoints – 52 wks Augment N=260 Autograft N=137 Non- Inferiority (p-value) SF-12 (Mean PCS) 42.4 45.0 Yes (<0.001) Foot Fusion Index (Mean Total) 20.1 17.5 Yes (0.012) AOFAS Ankle-Hindfoot Scale 77.8 78.2 Yes (<0.001) VAS Pain Scores Fusion Site 13.2 12.9 Yes (<0.001) Weight Bearing 15.6

Slide 17: Safety Endpoints
Safety Endpoints – 52 wks Augment N=272 Autograft N=142 P-value (Fisher Exact Test) Serious Treatment Emergent AE’s 10.3% 14.8% No difference (0.201) Complications (Surgically Related) 23.9% 30.3% No difference (0.195) Complications (Serious) 5.1% 6.3% No difference (0.654) Infections 8.5% 11.3% No

Slide 18: Pivotal Trial Data Summary
Pivotal Trial Data Summary Augment Bone Graft met the primary endpoint of the study – statistically significant non-inferiority to autograft per CT fusion rate at 24 wks 52 wk non-union rate ( 4.2% augment vs 5.8% autograft) is consistent with the published literature, despite high percentage of pat

Slide 19: Discussion/Conclusions
Discussion/Conclusions Harvesting autograft is a time-consuming procedure; which is associated with potential complications and prolonged post- operative patient pain Augment Bone Graft treated patients experienced fewer serious adverse events and were spared the pain and morbidity of bone graft har
Source: SEC EDGAR · 8-K filed Jul 7, 2010
More decks from Biomimetic Therapeutics Inc
31st Annual J.P. Morgan Healthcare Conference 201341 slides · Jan 8, 2013
Technical Presentation (June 2012)26 slides · Jun 21, 2012
Jefferies Global Healthcare Conference 201136 slides · Jun 10, 2011
Investor Day (February 2011)113 slides · Feb 23, 2011
Technical Presentation (July 2010)19 slides · Jul 7, 2010
Technical Presentation (March 2010)25 slides · Mar 12, 2010